Lv4
530 积分 2024-08-29 加入
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up
1天前
待确认
Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity
23天前
已完结
682-P: Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice
1个月前
已关闭
Glucagon receptor mRNA distribution in rat tissues
1个月前
已完结
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated
1个月前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
1个月前
已关闭
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
1个月前
已完结
phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
1个月前
已完结
Glucagon and glucagon-like peptide-1 dual agonist therapy: A possible future towards fatty kidney disease
1个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
1个月前
已完结
皖公网安备34019202002308
